Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2295
Source ID: NCT01968265
Associated Drug: Isis-Gccrrx
Title: Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: ISIS-GCCRRx|DRUG: Placebo
Outcome Measures: Primary: The effect of ISIS-GCCRRx on serum fructosamine, Change from Baseline to Week 7, 7 Weeks | Secondary: The safety of ISIS-GCCRRx, By determining the incidence, severity, adverse effects, and changes in laboratory evaluations, 18 Weeks|The tolerability of ISIS-GCCRRx, By determining the incidence, severity, adverse effects, and changes in laboratory evaluations, 18 Weeks
Sponsor/Collaborators: Sponsor: Ionis Pharmaceuticals, Inc.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 38
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2013-10
Completion Date: 2015-05
Results First Posted:
Last Update Posted: 2015-05-13
Locations: Isis Investigative Site, Red Deer, Alberta, Canada|Isis Investigative Site, Penticton, British Columbia, Canada|Isis Investigative Site, Cornwall, Ontario, Canada|Isis Investigative Site, Courtice, Ontario, Canada|Isis Investigative Site, Sudbury, Ontario, Canada|Isis Investigative Site, Montreal, Quebec, H2R1V6, Canada|Isis Investigative Site, Cluj Napoca, Cluj, 400349, Romania|Isis Investigative Site, Bucharest, 010507, Romania|Isis Investigative Site, Bucharest, 011794, Romania|Isis Investigative site, Bucharest, 022441, Romania|Isis Investigative Site, Bloemfontein, Free State, 9300, South Africa|Isis Investigative Site, Benoni, Gauteng, 1501, South Africa|Isis Investigative Site, Soweto, Gauteng, 1818, South Africa|Isis Investigative Site, Somerset West, Western Cape, 7130, South Africa
URL: https://clinicaltrials.gov/show/NCT01968265

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress